community-acquired pneumonia

According to international post-marketing trials, levofloxacin now belongs to the antimicrobial agents being in a great demand in clinical practice. One of the main indications for its use is community-acquired pneumonia (CAP). This review article is …

The article contains modern notions of epidemiology, course, clinical and diagnostic aspects of communityacquired pneumonia caused by Mycoplasma pneumoniae, standards of its treatment and antibiotic resistance of this pathogen in the world …

Objective. To conduct a cost-effectiveness analysis of combination of azithromycin with b-lactams (cefotaxime, ceftriaxone or amoxicillin/clavulanic acid) vs levofloxacin in hospitalized adults with community-acquired pneumonia (CAP). Materials and Methods. We performed standard search and meta-analysis of prospective clinical trials (CT) to compare clinical success rate and tolerability of regimens of antibacterial therapy (ABT) under the investigation. Direct medical costs (DC) including cost of ABT and hospital stay were calculated from the perspective of Smolensk Regional Clinical Hospital and Central Clinical Hospital of Russian Academy of Sciences.

The retrospective analysis of treatment of patients with severe community-acquired pneumonia has been performed. It has demonstrated that the results of therapy with generic preparations of ceftriaxone and levofloxacin were inferior to original drug …

Severe pneumonia is associated with high mortality rates, and appropriate severity assessment plays a main role in timely admission to the hospital, including intensive care unit. There are several scores for risk (poor outcome) assessment in …

Beta-lactams remain one of the most commonly used antimicrobial classes in the treatment of community-acquired respiratory tract infections worldwide. Among them, cephalosporins take one of the main places because of their broad spectrum of activity …

Choice of empiric therapy should be based on complex of data on etiology and local antimicrobial resistance trends as well as on clinical-economic analysis. According to our results, from the pharmacoeconomic point of view the most optimal agents for …

Community-acquired pneumonia (CAP) remains one of the most common and life-threatening infections. This paper represents a review of laboratory diagnosis of community-acquired pneumonia during the period of 2002– 2006. Local serological and …

The aim of the study was to determinate the structure of bacterial pathogens and their antimicrobial resistance in adult patients with community-acquired pneumonia (CAP). A total of 57 adult patients from Smolensk and Yartsevo hospitals with severe …

Community-acquired pneumonia (CAP) is the 4-8th leading killer of people worldwide and the most leading cause of death from infections in US. This article is a review of innovations and differences between the recent American Thoracic Society (ATS) …